Abstracts

549 – Plasma Cytokines and NF-κB Signaling Drive Transcriptomic Diversity in CD4+ T Cells From PWH on ART

Background Antiretroviral therapy (ART) is not a cure, and HIV rapidly rebounds upon ART interruption. Furthermore, people with HIV (PWH) on ART have elevated immune activation and inflammation which has been associated with increased risk of aging-associated diseases which may be driven by this viral persistence.  Methods To identify the potential mechanisms by which HIV…

505 – Sustained Post-Rebound HIV Remission With Enhanced T-Cell Immunity After LS-bNAbs: A Case Report

Background Non-human primate (NHP) models of HIV cure using HIV-specific broadly neutralising antibodies (bNAbs) describe viral control after an initial period of rebound, attributable to HIV-specific T cell responses – a ‘vaccinal effect’. There are examples of viral control after bNAbs in human studies, but no cases of post-bNAb viral rebound followed by sustained suppression,…

569 – The Cross Subtype Intact Proviral DNA Assay Detects 97% of Proviruses From Diverse HIV Clades

Background Intact proviral DNA assays (IPDA) are high-throughput methods to quantify intact and defective HIV proviruses during ART, with the former providing estimates of rebound-competent HIV reservoir. However, most IPDAs have been designed for subtype B and have ~28% false negative rate due to polymorphisms in the primer/probe sites1. The cross-subtype IPDA (CS-IPDA) was designed…

570 – Impact of Early ART Initiation With BIC/FTC/TAF on HIV-1 Reservoir Decay During Primary Infection

Background Viral reservoir is established early during primary HIV infection (PHI). Early antiretroviral therapy (ART) is essential to limit reservoir development. The aim of this work was to evaluate the impact of rapid bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) treatment on intact and defective proviral HIV-1 DNA in people with PHI. Methods Multicenter, single-arm clinical trial in confirmed…

571 – Rapid Clearance of the Inducible HIV-1 Reservoir After Initiation of Antiretroviral Therapy

Background Despite the cumulative expansion of the viral reservoir during untreated HIV-1 infection, it has been recently observed that the intact variants dated close to time of ART initiation predominate in the replicative-competent reservoir.  This observation indicates that there is a critical window period immediately following ART initiation that significantly shapes the composition of the…

581 – Thymosin α1 Enhances IL-15 Pathway Between MoDCs and CD8+ T Cells and Restrains HIV Latency In Vitro

Background Viral reservoir presents a significant challenge in HIV-1 cure. Studies indicate that dendritic cells may limit HIV-1 reservoir by bolstering CD8+ T cell function via the IL-15 pathway and facilitating the expansion of virtual memory CD8+ T cells (TVM). We previously observed that Thymosin α1 (Tα1) may restrict the reservoir through the IL-15 pathway,…

490 – Time to Viremia and Frequency of Post-Treatment Control Among 382 “Placebo-Treated” ATI Participants

Background There is a global need to explore novel interventions conferring sustained HIV control without antiretroviral therapy (ART). The only current strategy to test efficacy is through an analytical treatment interruption (ATI). Inclusion of ‘placebo’ controls in future clinical trials poses ethical, logistical, and economic challenges and might be unnecessary if sufficient up-to-date data exists…